CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
Chimeric antigen receptor (CAR)-engineered T lymphocytes (CAR Ts) produced impressive clinical results against selected hematological malignancies, but the extension of CAR T cell therapy to the challenging field of solid tumors has not, so far, replicated similar clinical outcomes. Many efforts are...
Main Authors: | Ramona Rotolo, Valeria Leuci, Chiara Donini, Anna Cykowska, Loretta Gammaitoni, Giovanni Medico, Giorgio Valabrega, Massimo Aglietta, Dario Sangiolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/11/2839 |
Similar Items
-
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
by: V. Leuci, et al.
Published: (2018-05-01) -
Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis
by: Yongyan Chen, et al.
Published: (2020-07-01) -
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective
by: Chiara Donini, et al.
Published: (2021-03-01) -
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
by: Giulia Mesiano, et al.
Published: (2018-11-01) -
The Influence of Innate Lymphoid Cells and Unconventional T Cells in Chronic Inflammatory Lung Disease
by: Jessica G. Borger, et al.
Published: (2019-07-01)